Retroviral Vector Production via Co-expressed Marker Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing lentiviral vectors are limited by inefficient stable integration of plasmids, suboptimal selection systems, and difficulty in determining relative expression levels of viral proteins in packaging cells, which hampers large-scale production suitable for clinical applications.
Innovation Solution
A retroviral production system that co-expresses viral proteins with detectable marker proteins, allowing for the selection of packaging cells with ideal expression ratios using flow cytometry, utilizing nucleic acid constructs with co-expression sequences and transposon elements for stable integration and marker-based sorting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stable integration of four plasmids is attempted through transient transfection followed by serendipitous integration, then packaging cell lines can be generated, but the integration efficiency is very low
Solution Approach 1:
The patent applies preliminary action by pre-designing nucleic acid constructs with built-in selection markers (antibiotic resistance genes) that are co-expressed with retroviral proteins. This allows cells to be pre-selected for successful integration events before viral production, dramatically improving integration efficiency from near-random serendipitous events to a targeted, efficient selection process.
Solution Approach 2:
The patent implements feedback mechanisms through the use of selectable markers that provide immediate biological feedback on successful plasmid integration. Cells that successfully integrate the nucleic acid constructs express antibiotic resistance, allowing for positive selection and enrichment of integrated cells, creating a feedback loop that drives efficient cell line generation.
2Reliability
If antibiotic selection is used to select for integration of four different genes, then cells with integrated plasmids can be identified, but the available selection systems are limited and not optimal
Solution Approach 1:
The patent applies segmentation by dividing the selection system into multiple independent selectable markers, each associated with a different retroviral gene (gag-pol, rev, env). This allows for modular selection where each marker can be independently optimized and combined, greatly increasing versatility compared to using a single antibiotic selection system.
Solution Approach 2:
The patent achieves universality by designing a multi-marker selection system where different antibiotic resistance genes can be used simultaneously or in combination. This multi-functional approach allows the same nucleic acid construct framework to support various selection strategies depending on the specific experimental needs, making the system adaptable to different scenarios.
3Reliability
If serendipitous integration events are used to generate stable packaging cell lines, then cells can be selected by antibiotic resistance, but it is difficult to determine the relative expression from each integration event
Solution Approach 1:
The patent applies the color changes principle by incorporating fluorescent protein markers (such as GFP, RFP, YFP) into the nucleic acid constructs alongside antibiotic resistance genes. These fluorescent markers provide visual and quantifiable information about expression levels through flow cytometry or microscopy, allowing researchers to distinguish between different expression levels without losing information about the integration events.
Solution Approach 2:
The patent uses fluorescent protein markers as intermediaries that bridge the gap between genetic integration and expression level measurement. These markers serve as mediators that convert internal gene expression states into externally detectable signals, enabling non-invasive monitoring and quantification of expression levels from individual integration events.
Data Source
Figure 1
Figure 2(a)~2(c)
Figure 2
AI summary
The present invention relates to a nucleic acid construct comprising: (i) a first nucleic acid sequence which either comprises a retroviral transfer vector or which encodes a retroviral protein; and (ii) a second nucleic acid sequence which encodes a detectable marker which is a cell surface protein comprising an extracellular domain and a membrane targeting domain.